Loading…
← CockpitCompetitor Analysis › 600252.SS Guangxi Wuzhou Zhongheng Group Co., Ltd. Class AOpen in the cockpit ↗

Guangxi Wuzhou Zhongheng Group Co., Ltd. Class A600252.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 71
Mkt cap
$936M
US dollars, full cap
Free float
72%
of shares outstanding
$/day
$33.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-10.4 pp
WACC 5.0%
Hurdle
+24 pp
Req g minus delivered
Close · CNYCN¥2.03
1D-1.9%
1W-10.2%
1M-6.0%
3M-14.7%
6M-10.2%
YTD-25.9%
1Y-27.0%
ATR %4.9%
52w lowhigh34.5% off high

What Guangxi Wuzhou Zhongheng does

Employees: 2,843

Guangxi Wuzhou Zhongheng at a glance

Size Guangxi Wuzhou Zhongheng (600252.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $936M, the 2284th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥2.03 on 18 Nov 2026.

Performance Over six months the shares fell 10.2%, against -18.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue fell 43.1% over the last twelve months (peer median +11.3%); the operating margin is -41.8% (peer median 8.8%).

Valuation It trades at 4.5× enterprise value to sales against a peer median of 3.8× (9th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is -14%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 10.4 points below its cost of capital (5.0% WACC).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026600252.SS 89Peer median 83
Six months, rebased to 100: Guangxi Wuzhou Zhongheng against the median of its 20 peers (local-currency closes).

Guangxi Wuzhou Zhongheng financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.30BCN¥1.74BCN¥2.09BCN¥3.07BCN¥2.69B
Revenue growth—-17%-32%+14%—
Gross profitCN¥671MCN¥660MCN¥863MCN¥1.77BCN¥1.48B
EBITDAn/a-CN¥178M-CN¥108MCN¥120MCN¥135M
Net income-CN¥419M-CN¥357M-CN¥377MCN¥84.3MCN¥79.0M
Free cash flowCN¥153M-CN¥17.8MCN¥389MCN¥317M-CN¥318M
Capital expenditureCN¥46.1MCN¥101MCN¥199MCN¥167MCN¥202M
Total debtCN¥763MCN¥1.77BCN¥1.98BCN¥1.79BCN¥1.97B

Quarterly statements and history in the cockpit →

Guangxi Wuzhou Zhongheng competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%600422002437688177603538STAR20050392003004011795MLTXIMTX30029425956887596885534565AKTS000597PGHLSPTX600252.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Guangxi Wuzhou Zhongheng is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×20×40×60×6004220024376881776035380392001795IMTX25954565AKTS600252.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guangxi Wuzhou Zhongheng is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%+30%0%20%002437603538STAR200503920030040117956885534565000597PGHL600252.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Guangxi Wuzhou Zhongheng is the large dot.

Guangxi Wuzhou Zhongheng competitors and peer comparison

How Guangxi Wuzhou Zhongheng compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guangxi Wuzhou Zhongheng against its 20 peers (data as of 18 Nov 2026)
Measure600252.SSPeer medianRank in peer set
1-month return-6.0%-9.1%7th highest of 21
6-month return-10.2%-18.9%7th highest of 21
Distance from 52-week high-34.5%-46.9%6th highest of 21
Revenue growth (TTM)-43.1%+11.3%3rd lowest of 18
Operating margin-41.8%8.8%5th lowest of 18
EV / Sales4.5×3.8×9th most expensive of 18
Growth the price implies (Req g, 7 yrs)10.3%7.7%5th most demanding of 12
Growth delivered (Del g)-13.7%+7.8%lowest of 12
Hurdle (Req g minus delivered)+24.0 pp-3.7 pp2nd most demanding of 12
ROIC minus cost of capital-10.4 pp-2.0 pp3rd lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%4.5×10.3%-13.7%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%1.8×n/an/a
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%6.5×n/an/a
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%2.6×-3.7%+13.8%
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%2.5×n/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Nxera Pharma 4565.TJapan$974M+46%+24%14%5.4×17.7%+27.3%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%6.3×5.6%+9.3%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a

Questions

Which companies are Guangxi Wuzhou Zhongheng's closest peers?
The cockpit's peer set: KPC Pharmaceuticals (600422.SS), Harbin Gloria Pharmaceuticals (002437.SZ), Bio-Thera Solutions (688177.SS), Ningbo Menovo Pharmaceutical (603538.SS), Strides Pharma Science (STAR.NS), SSY (2005.HK), Oscotec (039200.KS), Zhejiang Garden Biopharmaceutical (300401.SZ).
Is Guangxi Wuzhou Zhongheng expensive compared with its peers?
On ev / sales it trades at 4.5× against a peer median of 3.8×, 9th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is -14%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Guangxi Wuzhou Zhongheng stock performed?
Over six months to 18 Nov 2026 the shares returned -10.2% against -18.9% for the median peer; over one year -27.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.